Video

Dr. Ramalingam on Limitations With Immunotherapy in NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, deputy director, ​director, Lung Cancer Program, Winship Cancer Institute of Emory University, Roberto C. Goizueta Distinguished Chair for Cancer Research, professor, assistant dean for cancer research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses limitations with immunotherapy in non–small cell lung cancer (NSCLC).

Over the past few years, significant progress has been made with immunotherapy and targeted therapy in NSCLC, Ramalingam says. As a result, patients are now experiencing prolonged survival and improved quality of life.

However, only a small subset of patients will respond to immunotherapy, ​explains Ramalingam. As such, ​utilizing PD-L1 as a biomarker can help to predict which patients will benefit from immunotherapy. 

Ultimately, improv​ing the percentage of patients that benefit from checkpoint inhibitors remains an unmet need in NSCLC, ​says Ramalingam.

Additionally, developing novel therapies for patients who become resistant to checkpoint inhibitors should be a focus of future research efforts, Ramalingam concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity